A new vaccine will be administered for the first time in Wales today, with the aim of preventing hundreds of deaths and hospitalisations each year. The vaccine targets the respiratory syncytial virus (RSV), which takes the lives of between 400 and 600 adults annually and necessitates hospital treatment for over 1,000 babies. RSV is a prevalent infection that typically spreads in autumn and winter, affecting most children under two years old and often re-infecting older children and adults. While it may manifest as a common cold for many children, infants under one year are at higher risk of severe infection if they contract the virus. Studies indicate that the vaccine is safe and provides excellent protection against RSV.
Starting from September 2, adults over 75 and pregnant women at 28 weeks and beyond gestation will have the opportunity to receive the RSV vaccine. Eligible individuals will receive direct invitations or be directed by their midwives at antenatal clinics. The RSV vaccine becomes the fourth vaccination offered during pregnancy, alongside whooping cough, flu, and Covid-19, providing immunity to both mother and child. Dr. Christopher Johnson, Public Health Wales’ deputy director of health protection and head of the vaccine preventable disease programme, expressed enthusiasm for the vaccination rollout and highlighted the potential to safeguard the most vulnerable in Wales and the UK from the significant impact of the virus.
Cabinet Secretary for Health and Social Care, Mark Drakeford, stressed the importance of the RSV vaccine in mitigating health risks and reducing hospital admissions due to RSV-related illnesses. Dr. Mair Parry, a consultant paediatrician at Ysbyty Gwynedd in Bangor, welcomed the introduction of the RSV vaccine as a crucial measure to protect infants and vulnerable populations from severe RSV infections during the winter season. The vaccination programme aims not only to preserve well-being but also to alleviate pressure on healthcare services during peak periods.
The introduction of the RSV vaccine signifies a substantial advancement in public health efforts to combat the impact of respiratory infections, particularly among high-risk groups. The initiative underscores the proactive approach taken by Welsh health authorities to enhance preventive care and safeguard the well-being of the community.